Literature DB >> 25068656

Hepatic cytochrome P450 deficiency in mouse models for intrahepatic cholestasis predispose to bile salt-induced cholestasis.

Cindy Kunne1, Marijke de Graaff1, Suzanne Duijst1, Dirk R de Waart1, Ronald P J Oude Elferink1, Coen C Paulusma1.   

Abstract

Progressive familial intrahepatic cholestasis (PFIC) types 1 and 3 are severe cholestatic liver diseases caused by deficiency of ATB8B1 and ABCB4, respectively. Mouse models for PFIC display mild phenotypes compared with human patients, and this can be explained by the difference in bile salt pool composition. Mice, unlike humans, have the ability to detoxify hydrophobic bile salts by cytochrome P450-mediated (re)hydroxylation and thus have a less toxic bile salt pool. We have crossed mouse models for PFIC1 and PFIC3 with Hrn mice that have a reduced capacity to (re)hydroxylate bile salts. Double transgenes were obtained by backcrossing Atp8b1(G308V/G308V) and Abcb4(-/-) mice with Hrn mice that have a liver-specific disruption of the cytochrome P450 reductase gene and therefore have markedly reduced P450 activity. In these mice, a more hydrophobic bile salt pool was instilled by cholic acid supplementation of the diet, and bile formation and liver pathology was studied. As opposed to single transgenes, Atp8b1(G308V/G308V)/Hrn and Abcb4(-/-)/Hrn mice rapidly developed strong cholestasis that was evidenced by increased plasma bilirubin and bile salt levels. The bile salt pool was more toxic in both models; Atp8b1(G308V/G308V)/Hrn mice had a more hydrophobic plasma pool compared with the single transgene, whereas Abcb4(-/-)/Hrn mice had a more hydrophobic biliary pool compared with the single transgene. In line with these findings, liver damage was not aggravated in Atp8b1(G308V/G308V)/Hrn but was more severe in Abcb4(-/-)/Hrn mice. These data indicate that bile salt pool composition is a critical determinant in the initiation and progression of cholestasis and liver pathology in PFIC1 and PFIC3. Most importantly, our data suggest that the hydrophobicity of the plasma bile salt pool is an important determinant of the severity of cholestasis, whereas the hydrophobicity of the biliary bile salt pool is an important determinant of the severity of liver pathology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25068656     DOI: 10.1038/labinvest.2014.102

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  27 in total

1.  Assessment of peritoneal fibrosis by conventional light microscopy and hydroxyproline measurements.

Authors:  Roos van Westrhenen; Dirk R de Waart; Sema Akman; Raymond T Krediet
Journal:  Perit Dial Int       Date:  2004 May-Jun       Impact factor: 1.756

2.  Mutations in the MDR3 gene cause progressive familial intrahepatic cholestasis.

Authors:  J M de Vree; E Jacquemin; E Sturm; D Cresteil; P J Bosma; J Aten; J F Deleuze; M Desrochers; M Burdelski; O Bernard; R P Oude Elferink; M Hadchouel
Journal:  Proc Natl Acad Sci U S A       Date:  1998-01-06       Impact factor: 11.205

3.  Familial intrahepatic cholestasis 1: studies of localization and function.

Authors:  P Ujhazy; D Ortiz; S Misra; S Li; J Moseley; H Jones; I M Arias
Journal:  Hepatology       Date:  2001-10       Impact factor: 17.425

4.  Strain background modifies phenotypes in the ATP8B1-deficient mouse.

Authors:  Sohela Shah; Ukina R Sanford; Julie C Vargas; Hongmei Xu; Annamiek Groen; Coen C Paulusma; James P Grenert; Ludmila Pawlikowska; Saunak Sen; Ronald P J Oude Elferink; Laura N Bull
Journal:  PLoS One       Date:  2010-02-01       Impact factor: 3.240

5.  Identification of novel roles of the cytochrome p450 system in early embryogenesis: effects on vasculogenesis and retinoic Acid homeostasis.

Authors:  Diana M E Otto; Colin J Henderson; Dianne Carrie; Megan Davey; Thomas E Gundersen; Rune Blomhoff; Ralf H Adams; Cheryll Tickle; C Roland Wolf
Journal:  Mol Cell Biol       Date:  2003-09       Impact factor: 4.272

6.  ATP8B1 requires an accessory protein for endoplasmic reticulum exit and plasma membrane lipid flippase activity.

Authors:  Coen C Paulusma; Dineke E Folmer; Kam S Ho-Mok; D Rudi de Waart; Petra M Hilarius; Arthur J Verhoeven; Ronald P J Oude Elferink
Journal:  Hepatology       Date:  2008-01       Impact factor: 17.425

7.  ATP8B1 is essential for maintaining normal hearing.

Authors:  Janneke M Stapelbroek; Theo A Peters; Denis H A van Beurden; Jo H A J Curfs; Anneke Joosten; Andy J Beynon; Bibian M van Leeuwen; Lieke M van der Velden; Laura Bull; Ronald P Oude Elferink; Bert A van Zanten; Leo W J Klomp; Roderick H J Houwen
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-28       Impact factor: 11.205

8.  Regulation of biliary lipid secretion by mdr2 P-glycoprotein in the mouse.

Authors:  R P Oude Elferink; R Ottenhoff; M van Wijland; J J Smit; A H Schinkel; A K Groen
Journal:  J Clin Invest       Date:  1995-01       Impact factor: 14.808

9.  Quantitative estimation of the hydrophilic-hydrophobic balance of mixed bile salt solutions.

Authors:  D M Heuman
Journal:  J Lipid Res       Date:  1989-05       Impact factor: 5.922

10.  Defective bile salt biosynthesis and hydroxylation in mice with reduced cytochrome P450 activity.

Authors:  Cindy Kunne; Alexandra Acco; Simon Hohenester; Suzanne Duijst; Dirk R de Waart; Alaleh Zamanbin; Ronald P J Oude Elferink
Journal:  Hepatology       Date:  2013-01-18       Impact factor: 17.425

View more
  2 in total

1.  Uptake of glucose-conjugated MGMT inhibitors in cancer cells: role of flippases and type IV P-type ATPases.

Authors:  Karl-Heinz Tomaszowski; Nadja Hellmann; Viviane Ponath; Hiroyuki Takatsu; Hye-Won Shin; Bernd Kaina
Journal:  Sci Rep       Date:  2017-10-24       Impact factor: 4.379

2.  Glycochenodeoxycholate Promotes Liver Fibrosis in Mice with Hepatocellular Cholestasis.

Authors:  Simon Hohenester; Veronika Kanitz; Andreas E Kremer; Coen C Paulusma; Ralf Wimmer; Helen Kuehn; Gerald Denk; David Horst; Ronald Oude Elferink; Ulrich Beuers
Journal:  Cells       Date:  2020-01-23       Impact factor: 6.600

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.